Orcel Philippe
Fédération de rhumatologie, Centre Viggo Petersen, Hôpital Lariboisière, Paris (75).
Presse Med. 2006 Oct;35(10 Pt 2):1571-7. doi: 10.1016/s0755-4982(06)74853-9.
Corticosteroid-induced osteoporosis is common but too often unrecognized, and its management remains insufficient. Bone loss is variable from one patient to another and thus difficult to predict, but all treated patients must be considered at risk. There are tools to assess absolute fracture risk in this case as there are for menopause-associated osteoporosis, and they may help guide the clinician in decision-making. Recent guidelines help the physician to define indications for bone mineral density testing and for therapeutic management. Bisphosphonates are currently the first-line treatment for patients with fractures or elevated fracture risk during corticosteroid treatment.